Collectively, this research delineates that Aju-I mitigates pain behaviors in the streptozotocin (STZ)-induced diabetic neuropathy model by modulating the Nrf2/Keap-1/HO-1 signaling pathway and the activity of TRPV1/TRPM8 nociceptors (100). Here, TRPV1 is linked to diabetic neuropathy.